Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas

January 17, 2017
Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.
Previous Video
#DigMedShow & #MedtechShow 2017: Verily, Qualcomm, Proteus, Johnson & Johnson, Hogan Lovells
#DigMedShow & #MedtechShow 2017: Verily, Qualcomm, Proteus, Johnson & Johnson, Hogan Lovells

A holistic approach is critical to creating viable solutions for an efficient and effective healthcare syst...

Next Article
Rare diseases, rare commitment
Rare diseases, rare commitment

Patients, their families and patient foundations are invaluable in helping drug developers understand the d...